Blueprint Medicines up on positive trial data for bone-marrow disease drug

Blueprint Medicines

27/02/2023 19:53

** Shares of drugmaker Blueprint Medicines Corp  BPMC.O  up
3.8% at $39.43
    ** Co, late on Sunday reported positive data from a
registrational trial of its indolent systemic mastocytosis (SM)
treatment, AYVAKIT
    ** SM is a bone-marrow disorder in which white blood cells
accumulate in internal tissues and organs, and can cause organ
failure - NIH
    ** The treatment has shown rapid, durable and clinically
meaningful benefits across trial endpoints, with improvements
deepening over time, and a well-tolerated safety profile - Co 
    ** U.S. FDA granted priority review and has set a target
action date of May 22 for co's marketing application for AYVAKIT
in SM treatment, submitted in late November 2022
    ** In 2021, AYVAKIT, was approved by the FDA for treatment
of adults with advanced SM
    ** BPMC stock more than halved in value last year

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))